DenosuRel™ (Denosumab) is a human monoclonal antibody (IgG2) that binds to receptor activator of nuclear factor-kB ligand (RANKL), a protein that is essential for formation, function, and survival of osteoclast. It disrupts the RANKL/RANK interaction, prevents fusion and activation of osteoclasts, thus reducing bone resorption. It is produced in genetically engineered mammalian Chinese hamster ovarian (CHO) cells and has a molecular weight of 147 kDa.

DenosuRel™ is indicated in prevention of skeletal-related events in patients with multiple myeloma, or, in bone metastases from solid tumors, or, in hypercalcemia of malignancy refractory to bisphosphonate therapy. Bone metastasis and resorption of bone are common sequelae in these patients because of overexpression of protein RANKL.

DenosuRel™ (denosumab) is available in a single-use vial, as 120mg dose in 1.7ml solution.